This company launched a diagnostic assay, with leaders that all came from big pharma with zero diagnostic experience. With no strategy or understanding of the market they failed. The company will succeed long term because the Nanostring platform is amazing.
I heard they iced BrS and placed clinical sales under BarS with call point being pathology/admin . True?
Prosigna is the problem. You can blame sales all day, if the product doesn't have the data there is not much you can work with.
